Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Dedifferentiated liposarcoma: Which Medications Are Safest? (44 Drugs Compared)

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

44 medications are used for Dedifferentiated liposarcoma, with 190 combined adverse event reports. The most reported drugs for Dedifferentiated liposarcoma are DOXORUBICIN and SELINEXOR.

190
Total Reports
44
Drugs Used

All Medications for Dedifferentiated liposarcoma Ranked by Safety Reports

Drug Brand Reports Deaths (all) Hosp. (all) Death Rate
DOXORUBICIN Doxorubicin Hydrochloride 40 15,653 28,630 18.9%
SELINEXOR XPOVIO 32 1,264 2,359 17.0%
TRABECTEDIN YONDELIS 28 376 896 19.2%
IFOSFAMIDE IFEX 24 3,365 5,230 19.8%
PALBOCICLIB Ibrance 23 11,066 13,442 12.2%
ERIBULIN eribulin mesylate 16 793 2,642 15.7%
GEMCITABINE Gemcitabine 13 5,142 12,268 16.4%
UNSPECIFIED INGREDIENT - 11 6,132 11,236 23.4%
NIVOLUMAB OPDIVO 9 23,086 36,530 26.3%
DOCETAXEL Docetaxel 7 6,068 13,463 9.3%
INVESTIGATIONAL PRODUCT - 6 740 4,035 13.8%
IPILIMUMAB YERVOY 6 8,043 17,031 22.0%
REGORAFENIB Stivarga 6 1,869 3,363 19.8%
PAZOPANIB Pazopanib 5 5,612 4,347 26.5%
PEMBROLIZUMAB KEYTRUDA 5 15,543 35,472 18.6%
RIBOCICLIB KISQALI 5 4,501 6,700 16.1%

View all 44 drugs →

Most Reported Drugs for Dedifferentiated liposarcoma

#1 most reported
#2 most reported
#3 most reported